Dyadic International Inc. is selling its industrial technology business to DuPont’s Industrial Biosciences business for $75 million. Dyadic says it intends to focus exclusively on its biopharmaceutical business. “This transaction is an exceptional opportunity to unlock value and provide Dyadic operational flexibility to further develop our pharmaceutical business,” said Mark Emalfarb, founder and chief executive officer, Dyadic. “We will now focus our C1 technology exclusively on the pharmace...